BA
The Boeing Company
BA has lower modeled downside risk, despite its lower overall score.
ENOV
Enovis Corporation
ENOV has a slight edge over BA overall, supported by stronger modeled upside.
BA Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Under pressure |
BA's profitability is currently healthy, and its revenue and cash flow are stable, but its balance sheet is under pressure.
ENOV Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Healthy | |
| Healthy |
ENOV's cash flow and balance sheet are currently healthy, and its revenue is stable, but its profitability is under pressure.
BA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 18x | $172 | — |
| Cheap | 51x | $496 | +189% |
| Fair | 82x | $790 | +360% |
| Expensive | 91x | $876 | +411% |
Historical ranges are pointers, not guarantees.
BA's PE is 18x, but its earnings don't support one, so it isn't a reliable read right now.
ENOV PE Valuation
ENOV has no meaningful PE right now: it lost money over the past year.
BA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Growth | |
| Improving | |
| Limited | |
| Low |
Analysts expect BA to return to profit, with revenue growing. However, they disagree widely on these estimates.
ENOV Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for ENOV, with profitability improving.
BA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $9.66 | +$23.38 |
| Q2 2026 | $2.78 | +$19.33 |
| Q1 2026 | $2.53 | +$20.49 |
| Q4 2025 | $2.48 | +$20.84 |
| Q3 2025 | -$13.72 | -$0.83 |
| Q2 2025 | -$16.55 | -$10.93 |
| Q1 2025 | -$17.96 | -$14.42 |
| Q4 2024 | -$18.36 | -$14.69 |
BA has the edge over ENOV on earnings quality, reporting a profit while its opponent remains loss making.
ENOV Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.56 | — |
| Q3 2026 | -$9.25 | +$15.05 |
| Q2 2026 | -$19.30 | -$4.41 |
| Q1 2026 | -$19.92 | -$5.33 |
| Q4 2025 | -$20.75 | -$5.82 |
| Q3 2025 | -$24.30 | -$22.11 |
| Q2 2025 | -$14.89 | -$13.23 |
| Q1 2025 | -$14.59 | -$13.09 |
| Q4 2024 | -$14.93 | -$14.32 |
ENOV is still losing money, but far less than before: $9.25 per share over the past year, against $24.30 at its worst in late 2025.
BA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.2B | +3.9% |
| Q2 2026 | $24.6B | +8% |
| Q1 2026 | $22.2B | +14% |
| Q4 2025 | $23.9B | +57% |
| Q3 2025 | $23.3B | +30% |
| Q2 2025 | $22.7B | +35% |
| Q1 2025 | $19.5B | +18% |
| Q4 2024 | $15.2B | -31% |
BA's revenue has grown year over year for seven quarters in a row: $24.2B last quarter, up 3.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 1.5% | +22 points |
| Q2 2026 | 0.6% | +1.4 points |
| Q1 2026 | 2% | -0.3 points |
| Q4 2025 | 37% | +61 points |
| Q3 2025 | -21% | +12 points |
| Q2 2025 | -0.8% | +5.7 points |
| Q1 2025 | 2.4% | +2.9 points |
| Q4 2024 | -25% | -26 points |
BA has the edge over ENOV on profitability, with a higher operating margin.
ENOV Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $558.7M | +1.8% |
| Q2 2026 | $582.8M | +3.2% |
| Q1 2026 | $589.2M | +5.4% |
| Q4 2025 | $575.8M | +2.6% |
| Q3 2025 | $548.9M | +8.6% |
| Q2 2025 | $564.5M | +7.5% |
| Q1 2025 | $558.8M | +8.2% |
| Q4 2024 | $561M | +23% |
ENOV's revenue has grown year over year for 14 quarters in a row: $559M last quarter, up 1.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 0.6% | +102 points |
| Q2 2026 | 3% | +6 points |
| Q1 2026 | 1.1% | +9.5 points |
| Q4 2025 | -87% | +31 points |
| Q3 2025 | -102% | -96 points |
| Q2 2025 | -3% | +5.4 points |
| Q1 2025 | -8.4% | -1.6 points |
| Q4 2024 | -119% | -117 points |
ENOV's operating margin was 0.6% last quarter, up 102 points from the same quarter a year ago.
BA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $464M | +95% |
| Q2 2026 | $631M | +$831M |
| Q1 2026 | -$1.5B | +$836M |
| Q4 2025 | $375M | +$4.5B |
| Q3 2025 | $238M | +$2.2B |
| Q2 2025 | -$200M | +$4.1B |
| Q1 2025 | -$2.3B | +$1.6B |
| Q4 2024 | -$4.1B | -239% |
BA has the edge over ENOV on cash flow, with more consistent year-over-year improvement.
ENOV Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $35M | +20% |
| Q2 2026 | $31.1M | +816% |
| Q1 2026 | -$28.9M | +$16M |
| Q4 2025 | $32.3M | -8.1% |
| Q3 2025 | $29.1M | +1128% |
| Q2 2025 | $3.4M | +$35M |
| Q1 2025 | -$44.9M | +$28.2M |
| Q4 2024 | $35.1M | -13% |
ENOV still generates free cash flow, though less than at its 2020 peak: $70M over the past year.
BA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +2.1M shares |
| 1 year | +4.3% | +32.8M shares |
| 3 years | +31% | +186M shares |
| 5 years | +35% | +204M shares |
| Available history | +40% | +227M shares |
BA has 793M diluted shares, up 4.3% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
ENOV Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.5% | +892K shares |
| 1 year | +2.3% | +1.3M shares |
| 3 years | +7.2% | +3.9M shares |
| 5 years | +8.9% | +4.8M shares |
| Available history | +28% | +12.9M shares |
ENOV has the edge over BA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
BA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.0x | Elevated |
| Q2 2026 | 5.7x | High |
| Q1 2026 | 6.0x | High |
| Q4 2025 | 6.9x | High |
| Q2 2024 | 361.8x | High |
| Q1 2024 | 36.1x | High |
| Q4 2023 | 36.4x | High |
| Q3 2023 | 96.1x | High |
BA's net debt is about 3.0 years of its operating earnings (EBITDA), down from more than 20 years a year ago.
ENOV Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.4x | Healthy |
| Q2 2026 | 4.1x | High |
| Q1 2026 | 4.7x | High |
| Q4 2025 | 5.7x | High |
| Q2 2025 | 7.9x | High |
| Q1 2025 | 6.6x | High |
| Q4 2024 | 8.4x | High |
| Q3 2024 | 8.7x | High |
ENOV has the edge over BA on leverage, with a lower net debt burden relative to earnings.
BA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 31.1 | Neutral |
| Stochastic | 9.6 | Oversold |
BA's weekly RSI is 31 (neutral) and its Stochastic is 10 (oversold).
ENOV Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 60.6 | Neutral |
| Stochastic | 58.1 | Neutral |
ENOV's weekly RSI is 61 (neutral) and its Stochastic is 58 (neutral).
BA PE vs Industrials Sector
| Metric | BA | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 24x | 26% below |
| PE % | 0 | 58 | 58 pts below |
BA is trading at 18x earnings, a 26% discount to the Industrials sector's median of 24x, though its earnings don't support one.
ENOV PE vs Industrials Sector
| Metric | ENOV | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 24x | — |
ENOV has no meaningful PE right now: it lost money over the past year.
BA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $184.6 | 7.1% below |
| 20 week MA | $203.8 | 16% below |
| 50 week MA | $215.5 | 20% below |
| 100 week MA | $205.9 | 17% below |
| 200 week MA | $200.6 | 14% below |
BA is in a downtrend: it's below all five of its weekly moving averages, and 14% below its 200-week average.
ENOV Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $21.2 | 31% above |
| 20 week MA | $23.0 | 20% above |
| 50 week MA | $23.7 | 17% above |
| 100 week MA | $29.2 | 5.2% below |
| 200 week MA | $41.1 | 33% below |
ENOV has the edge over BA on trend strength, trading above more of its moving averages.
BA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $330.1 | $217.2 | -34% |
| 2021 | $217.2 | $204.2 | -6% |
| 2022 | $204.2 | $189.1 | -7.4% |
| 2023 | $189.1 | $260.7 | +38% |
| 2024 | $260.7 | $180.7 | -31% |
| 2025 | $180.7 | $216.4 | +20% |
| 2026 YTD | $216.4 | $171.6 | -21% |
BA has finished lower in four of the last six years. It's down 21% so far in 2026.
ENOV Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $62.5 | $63.3 | +1.4% |
| 2021 | $63.3 | $77.7 | +23% |
| 2022 | $77.7 | $52.9 | -32% |
| 2023 | $52.9 | $56.0 | +6% |
| 2024 | $56.0 | $44.3 | -21% |
| 2025 | $44.3 | $27.4 | -38% |
| 2026 YTD | $27.4 | $27.6 | +0.9% |
ENOV has the edge over BA on returns for 2026, with the stronger performance.